MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022
MINDCURE announces its Q1 fiscal 2022 results, including initial release of its iSTRYM platform. Cash and equivalents of CAD$15.6 million as of August 31, 2021.
Psychedelics Clinics Race Gaining Momentum
The rapidly expanding networks of psychedelics-based treatment clinics is a horse race where EVERYONE is a winner.
MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program
MindMed announces a new R&D initiative focused on an MDMA derivative, and aimed at treating social anxiety.
Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology
Cybin receives IND authorization from the FDA to study ketamine's psychedelic effect on the cerebral cortex.
Levitee Labs Enters into Credit Facility For Up To $12 Million
Levitee Labs announces new credit facility for up to CAD$12 million to finance expansion of its clinics network.
The Psychedelics Revolution is EVERYWHERE
Psychedelic drugs are all over the news. Not just general news but also business media. Big news. Big Business.
Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder
The UK drug regulator (MHRS) has granted Small Pharma Fast-Track Designation with respect to SPL026 for Major Depressive Disorder (MDD).
Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up?
Cash-rich psychedelic stocks are cheap. They are also building value for investors -- at an accelerating rate.
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
Numinus prepares for a Phase I clinical trial of its proprietary psilocybin extract.
Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility
Small Pharma announces receiving DTC Eligibility and its OTCQB listing to broaden liquidity and increase access for U.S. investors.
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies
Cybin has completed its 74th pre-clinical study and anticipates commencing human clinical studies in early 2022.
